SunTrust Robinson Humphrey continues to expand its Equity Research team with the hiring of four experienced analysts covering the biotechnology and medical device industries. These additions bolster STRH’s research expertise and capability, and are a key part of the industry-leading content aggregation within Equity Research.    
 
“The healthcare sector, particularly the biotechnology and medical device industries, remain strong growth areas for the U.S. economy and of the utmost interest to our institutional client base. We’re investing in industry-leading talent to serve the needs of existing and prospective clients. We are very pleased to welcome these teammates, who have a broad range of financial services and industry experience,” said Robert Popowski, managing director and head of Sales, Trading & Research at STRH.
 
Bruce Nudell joins STRH as a managing director, responsible for coverage of the Medical Device sector, based in Atlanta. Nudell is a revered industry expert, as he has more than 14 years of Wall Street experience as a senior publishing research analyst, as well as 18 years of corporate experience in strategic planning and project management roles working within science and medical labs. He earned a BA from Northwestern University, a Masters in Finance from the University of Colorado, as well as a PhD in Cellular Electrophysiology at the University of California, Los Angeles.
 
Peter Lawson joins STRH as a director covering Biotech. Lawson was most recently a senior healthcare analyst at Mizuho Securities, where he covered both Biotechnology and the Diagnostic Tools areas. His prior experience includes six years at Thomas Weisel Partners, where he covered Healthcare Tools and Diagnostics, initially as an associate and eventually as a senior analyst. Lawson earned a PhD from Oxford University, and spent four years in a post doctorate fellowship at the Cancer Research Institute at the Albert Einstein College of Medicine. His academic expertise in oncology and immunology will be key to meeting STRH’s goal of becoming a thought leader in drug development in these key therapeutic categories.
 
Yatin Suneja joins STRH as a director providing Biotech research coverage. Suneja was most recently at Cowen and Company, where he spent the last four years covering Biotech stocks. Prior to Cowen, he was a key member of the Biotech team at Rodman & Renshaw LLC, where he covered a broad range of companies, wrote influential white papers on key therapeutic categories, and supported the build out of that firm’s Biotech practice. He earned an MBA from Syracuse University and a Bachelor of Commerce from PGDAV College, University of Delhi.
                                                                                                                                                      
Imron Zafar joins STRH as a vice president covering the Medical Devices and Technology space.  Zafar brings 15 years of sell-side equity research experience. For the past five years, he was a member of the Medical Devices and Technology team at Jefferies and Company, covering over 35 stocks in multiple therapeutic areas and market caps. Previously he worked with the Med Tech team at Deutsche Bank for seven years and with the Chemicals team at Credit Suisse First Boston. He earned a BA in Neuroscience at Amherst College.